Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target

Benzinga Newsdesk www.benzinga.com Negative 73.5%

Neg 73.5% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $35 price target.